Patents Examined by Noble E Jarrell
  • Exon 18 and/or exon 21 mutant EGFR selective inhibitor
    Patent number: 11701359
    Abstract: An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 18, 2023
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Naomi Abe, Shinichi Hasako
  • Methods to purify cannabinoids
    Patent number: 11702397
    Abstract: Various aspects of this patent document relate to the rapid purification of cannabinoids by vaporization and condensation.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: July 18, 2023
    Assignee: NATURAL EXTRACTION SYSTEMS, LLC
    Inventors: C. Russell Thomas, Matthew M. DePalo
  • Macrocyclic deaza-purinones for the treatment of viral infections
    Patent number: 11702426
    Abstract: This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: July 18, 2023
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jean-François Bonfanti, Jérôme Michel Claude Fortin, Philippe Muller, Frédéric Marc Maurice Doublet, Pierre Jean-Marie Bernard Raboisson, Eric Pierre Alexandre Arnoult
  • Rifamycin analogs and antibody-drug conjugates thereof
    Patent number: 11666658
    Abstract: The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: June 6, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Thomas Nittoli, Seungyong Sean Choi, Mrinmoy Saha
  • Antiestrogen compounds
    Patent number: 11667621
    Abstract: A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 6, 2023
    Assignees: STEVENS INSTITUTE OF TECHNOLOGY, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Abhishek Sharma, Sarat Chandarlapaty, Lucia Wang, Shengjia Lin, Weiyi Toy, John Katzenellenbogen
  • 1,4-disubstituted imidazole derivative
    Patent number: 11661397
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 30, 2023
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • Substituted benzene compounds
    Patent number: 11642348
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • Gas phase methods to decarboxylate cannabinoids
    Patent number: 11643402
    Abstract: Various aspects of this disclosure relate to gas phase methods to decarboxylate cannabinoid carboxylic acids.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: May 9, 2023
    Assignee: NATURAL EXTRACTION SYSTEMS, LLC
    Inventors: C. Russell Thomas, Matthew M. DePalo
  • Histone demethylase inhibitors
    Patent number: 11639333
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: May 2, 2023
    Assignee: CELGENE QUANTICEL RESEARCH, INC
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Inhibitors of activin receptor-like kinase
    Patent number: 11634422
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 25, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • Micheliolide derivatives, methods for their preparation and their use as anticancer and antiinflammatory agents
    Patent number: 11634400
    Abstract: The present invention relates to derivatives of the sesquiterpene lactone micheliolide, methods and compositions for their preparation, and methods for using the micheliolide derivatives in pharmaceutical compositions as anticancer and anti-inflammatory agents. The invention also relates to methods for producing micheliolide derivatives modified at positions C2 and C14. The invention also relates to methods for producing parthenolide derivatives modified at positions C2 and C14 in conjunction with modifications at position C13, via chemoenzymatic methods. The invention further relates to methods for using parthenolide derivatives for treating cancer and inflammatory diseases.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 25, 2023
    Assignee: University of Rochester
    Inventors: Rudi Fasan, Simone Giovani, Hanan Alwaseem
  • Peptide conjugates of cytotoxins as therapeutics
    Patent number: 11634508
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: April 25, 2023
    Assignee: Cybrexa 2, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • Lanthanide metal chelate security feature
    Patent number: 11629290
    Abstract: A chelate and associated security feature including a lanthanide metal and a ligand of formula (1), formula (2), or formula (3), where each of R1-R7 in formula (1) is independently selected from the group consisting of H, OH, NH2, Cl, F, OMe, OAr, OCF3, CF3, alkyl, aryl, phenyl, OPh, and heteroaromatic, where each of R1-R5 in formula (2) is independently selected from the group consisting of H, OH, NH2, Cl, F, OMe, OAr, OCF3, CF3, NMe2, CN, alkyl, aryl, phenyl, OPh, and heteroaromatic, and where R6 in formula (2) is selected from the group consisting of H, NH2, Cl, F, OMe, OAr, OCF3, CF3, NMe2, CN, alkyl, aryl, phenyl, OPh, and heteroaromatic, and where each of R1-R5 in formula (3) is independently selected from the group consisting of H, OH, NH2, Cl, F, OMe, OAr, OCF3, CF3, alkyl, aryl, phenyl, OPh, and heteroaromatic.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: April 18, 2023
    Assignee: Spectra Systems Corporation
    Inventors: Andriy Smuk, Michael Bradlee
  • Method for producing optically active substance, optically active substance, method for producing chiral molecule, and chiral molecule
    Patent number: 11603337
    Abstract: Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: March 14, 2023
    Assignees: DAICEL CORPORATION, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Katsuhiko Tomooka, Kazunobu Igawa
  • Macrocyclic ligands with pendant chelating moieties and complexes thereof
    Patent number: 11603371
    Abstract: The invention relates to ligands and complexes of metal ions with the ligands useful in various applications, including therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: March 14, 2023
    Assignee: LUMIPHORE, INC.
    Inventors: David Tatum, Jide Xu, Darren Magda, Nathaniel Butlin
  • Method for producing purified dialkyl-furan-2,5-dicarboxylate
    Patent number: 11603360
    Abstract: Disclosed is a purified dialkyl furan dicarboxylate (DAFD) vapor composition containing at least 99.5 wt. % DAFD; 5-(alkoxycarbonyl) furan-2-carboxylic acid (ACFC) that, if present, is present in an amount of not more than 1000 ppm, alkyl-5-formylfuran-2-carboxylate (AFFC) that, if present, is present in an amount of not more than 1000 ppm, 5-(dialkoxymethyl)furan-2-carboxylic acid (DAFCA) that if present, is present in an amount of not more than 1000 ppm, and alkyl 5-(dialkoxymethyl)furan-2-carboxylate (ADAFC) that if present, is present in an amount of not more than 1000 ppm, in each case based on the weight of the DAFD vapor composition.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 14, 2023
    Assignee: Eastman Chemical Company
    Inventor: Mesfin Ejerssa Janka
  • PD-L1/STING conjugates and methods of use
    Patent number: 11596692
    Abstract: The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhenwu Li, Wenqing Yao
  • Composition containing furfuryl silicates and furfuryl alcohol
    Patent number: 11591264
    Abstract: Described are a composition comprising furfuryl silicates and furfuryl alcohol, especially for use as acid-curable binder, and processes for producing such a composition.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: February 28, 2023
    Assignee: HÜTTENES-ALBERTUS CHEMISCHE WERKE GESELLSCHAFT MIT BESCHARÄNKTER HAFTUNG
    Inventors: David Strunk, Christian Fourberg, Gérard Ladégourdie, Norbert Benz
  • Modulators of hemoglobin
    Patent number: 11548880
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 10, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventor: Zhe Li
  • Methods and compositions for inhibiting the interaction of menin with MLL proteins
    Patent number: 11542248
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 3, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock